Search results for " Wilms Tumor"

showing 3 items of 3 documents

The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation.

1999

Gonadal differentiation is dependent upon a molecular cascade responsible for ovarian or testicular development from the bipotential gonadal ridge. Genetic analysis has implicated a number of gene products essential for this process, which include Sry, WT1, SF-1, and DAX-1. We have sought to better define the role of WT1 in this process by identifying downstream targets of WT1 during normal gonadal development. We have noticed that in the developing murine gonadal ridge, wt1 expression precedes expression of Dax-1, a nuclear receptor gene. We document here that the spatial distribution profiles of both proteins in the developing gonad overlap. We also demonstrate that WT1 can activate the D…

Transcriptional Activationcongenital hereditary and neonatal diseases and abnormalitiesGenes Wilms TumorReceptors Retinoic AcidTATA boxMolecular Sequence DataMutagenesis (molecular biology technique)Biologyurologic and male genital diseasesResponse ElementsTransactivationMiceGene expressionAnimalsHumansGonadsPromoter Regions GeneticWT1 ProteinsMolecular BiologyGeneCell Growth and DevelopmentCell Line TransformedGonadal ridgeBase Sequenceurogenital systemDAX-1 Orphan Nuclear ReceptorfungiGene Expression Regulation DevelopmentalCell Biologyfemale genital diseases and pregnancy complicationsCell biologyDNA-Binding ProteinsRepressor ProteinsTestis determining factorNuclear receptorCOS CellsCancer researchTranscription FactorsMolecular and cellular biology
researchProduct

Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell su…

2008

Background We evaluated an intensified chemotherapy strategy in children with Wilms tumor who relapsed with high-risk features. Procedures From January 2001 to June 2006, we treated 20 consecutive children with reinduction chemotherapy (using ifosfamide/carboplatin/etoposide in 15/20 cases), with (n = 15) or without (n = 5) subsequent high-dose chemotherapy and hematopoietic stem cell support, surgery where feasible, and radiation therapy. The median time to relapse was 10 months after nephrectomy. All but two children initially received doxorubicin as first-line therapy. Results All patients were assessed for outcome: 13 are currently alive, 12 of them in remission a median 25 months since…

OncologyMaleTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationNephrectomyPediatricschemistry.chemical_compoundHigh-dose chemotherapyRelapseChildIfosfamideGraft SurvivalRemission InductionHematopoietic Stem Cell TransplantationHematologyPerinatology and Child HealthSurvival RateTreatment OutcomeItalyOncologyChild PreschoolAbsolute neutrophil countFemaleAutologousmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsTransplantation AutologousWilms TumorInternal medicinemedicineHumansPreschoolSurvival rateSalvage TherapyChemotherapyTransplantationbusiness.industryInfantWilms' tumormedicine.diseaseCarboplatinSurgeryRadiation therapychemistryPediatrics Perinatology and Child HealthAutologous hematopoietic stem cell transplantation; High-dose chemotherapy; Relapse; Wilms tumor; Antineoplastic Agents; Child; Child Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Italy; Male; Nephrectomy; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation Autologous; Treatment Outcome; Wilms Tumor; Pediatrics Perinatology and Child Health; Hematology; OncologybusinessAutologous hematopoietic stem cell transplantation
researchProduct

Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.

2013

Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transd…

Genes Wilms TumorCell SurvivalGenetic VectorsAntineoplastic AgentsBiologyCD8-Positive T-LymphocytesLymphocyte ActivationPeripheral blood mononuclear cellEpitopeMonocytesViral vectorMiceAntigenRisk FactorsGeneticsmedicineNeoplasmAnimalsHumansMolecular BiologyResearch ArticlesOligonucleotide Array Sequence AnalysisCD86LentivirusGene Transfer TechniquesMyeloid leukemiaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationDendritic CellsGenetic Therapymedicine.diseaseAdoptive TransferLeukemia Myeloid AcuteGene Expression RegulationCancer researchLeukocytes MononuclearMolecular MedicineInterleukin-4Ex vivoHuman gene therapy
researchProduct